Latest Content

FDA approves Opdivo with AVD for stage 3 or 4 Hodgkin lymphoma after trial shows improved progression-free survival versus comparator in untreated patients.

A couple shares how open communication reshaped their relationship during and after liver cancer treatment.

We often face difficult decisions with patients and family members. Are the side effects of treatment worth the benefits? Is cure achievable, and at what cost?

For Kathy Small Wrice, a 20-year journey with multiple myeloma began not with a clear answer, but with a persistent intuition.

Patients with cancer are referred for psychosocial support to address emotional distress and mental health needs, according to a new study.

Shondia McFadden-Sabari of Bold and Breastless shares how intuition and early detection saved her life during a dual breast cancer diagnosis.

Talzenna plus Xtandi improved progression-free survival in metastatic prostate cancer, delaying disease worsening in a phase 3 trial.

New strategies in mCRPC focus on sequencing, genomics and earlier use of targeted therapies to improve outcomes for patients.

A phase 3 study shows pimicotinib shrinks tumors and improves pain, stiffness and mobility in adults with unresectable tenosynovial giant cell tumors.

Rosemary Carrera discusses her breast cancer journey, mastectomy and the personal decision to remove her implants at the Miami Breast Cancer Conference.

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact.